# R-5280 in Newly Diagnosed Patients With Type 1 Diabetes

> **NCT06057454** · PHASE1 · COMPLETED · sponsor: **Rise Therapeutics LLC** · enrollment: 9 (actual)

## Conditions studied

- Type 1 Diabetes
- Type 1 Diabetes (Juvenile Onset)
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** R-5280
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06057454
- **Lead sponsor:** Rise Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-05
- **Primary completion:** 2025-11-05
- **Final completion:** 2025-11-05
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06057454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06057454, "R-5280 in Newly Diagnosed Patients With Type 1 Diabetes". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06057454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*